We’re on a short summer break! Marijuana Today will be back with fresh new episodes the week of July 8th. Enjoy the start of summer! Produced by Shea Gunther.
Category: adult use
Auto Added by WPeMatico
Guest Dr. Jahan Marcu speaks with host Heather Sullivan about a recent bibliometric study on cannabis finding an increase in legal marijuana research as well as the science behind a recent appeals court ruling making Delta 8 THC legal. Produced by Shea Gunther.
To date, legal cannabis in America has been understood one of two ways: medicine, or fun. There’s medical marijuana, requiring a qualifying condition and a doctor’s recommendation before any legal weed can be accessed; and then there’s adult-use cannabis (or recreational), requiring nothing but a government-issued ID proving one’s age.
But what if there’s a third way—or, what if, as the late activist Dennis Peron used to say, all marijuana use was medical, or at least part of a general wellness strategy? Recent research that demonstrates a drop in prescription-drug use in states that legalized adult-use cannabis—which, as a convenient bonus, is generally more easily and more widely available than medical—suggests this may be the case.
Weed Up, Pills Down
In the past, the passage of medical cannabis laws has been associated with a drop in prescription pharmaceuticals. The effect of adult-use cannabis laws—no small deal in East Coast states such as New York, where the medical program is small and difficult to access thanks to tight restriction around physicians and qualifying illnesses–-is less studied.
So, researchers looked at Medicaid prescriptions filled between 2011 and 2019 in all 50 states. And in states that legalized adult-use cannabis, they found “significant reductions” in prescriptions filled for drugs meant to treat “pain, depression, anxiety, sleep, psychosis and seizures,” according to a research article published in April in the journal Health Economics.
Or, put another way, legalization seems to present a significant medical benefit along with the familiar arguments for social justice and new sources of tax revenue.
People are self-medicating with cannabis, and while it’s hard to say for certain whether they’re achieving the same results, the fact that they don’t seem to be returning to pharmaceuticals is suggestive, as study co-author Shyam Raman, a PhD student at Cornell University’s Jeb E. Brooks School of Public Policy, said in a recent interview.
“What [adult-use cannabis] legalization does is open up an opportunity to self-medicate without seeing a doctor and potentially be denied because your sickness isn’t on the qualifying condition list,” said Raman, who stressed that while only Medicaid data was studied, these results are applicable to the general population. “There’s some real evidence people are self-medicating, and people aren’t switching back to pharmaceuticals.”
Cannabis for Anxiety, Depression and Insomnia
Among the drug classes studied, Raman and study co-author Ashley Bradford, a researcher and PhD student at Indiana University, saw the steepest drops in demand for anxiety, depression, insomnia and psychosis, with drops of 12.2%, 11.1%, 10.8% and 10.7%, respectively.
In addition to potential cost-savings for Medicaid programs, adult-use cannabis legalization may present an additional harm-reduction benefit, the researchers found, with people dropping or reducing reliance on pharmaceutical drugs with nasty side effects as easier-to-access “over-the-counter” recreational cannabis becomes available.
“We believe that quite strongly, that people are doing it because the side effects of pharmaceuticals are really frustrating,” Raman said.
The findings suggest adopting both a more sophisticated and expansive understanding of adult-use cannabis legalization—and never neglecting the fact that no matter what you call it, cannabis generally may be a wellness product, a fact that advocates pushing for adult-use cannabis legalization on the state and federal levels shouldn’t neglect.
“The adult-use cannabis market in most states is just easier to utilize, because patients don’t have to pay for a patient card and they don’t have to get a doctor’s recommendation,” said Debbie Churgai, executive director of Americans for Safe Access, arguably the country’s leading medical-first cannabis policy advocacy group.
But, as always, it’s also a reminder that cannabis is badly under-researched. Key questions including dosage and regimen remain unanswered, leaving “patients”—regardless of whether they’re official enrollees in their state’s program—to figure it out for themselves.
“We still don’t know how to regulate cannabis as a medicine,” Raman said. “How are we in a position to say, ‘This is medical,’ without being able to say, ‘This is the amount you take for therapeutic use’?”
Always Medical, Or Wellness Benefit?
So, is cannabis always medical, or is all recreational cannabis also medical, or is a third way of understanding cannabis the best classification? It’s hard to say for certain—and ultimately it may not matter.
“I don’t like to compare [medical and adult-use cannabis],” Churgai said. “I think this is a great example of how people are feeling the effects of the medicine whether they recognize it or not.”
But what this does suggest is that certain forces in the cannabis industry might need to re-evaluate their messaging and branding. Don’t forget about the medical cannabis patients: they’re part of your adult-use market segment, too.
“If you go to these business conferences, you barely even see or hear the word ‘patient’ in any presentation,” Churgai said. “I do think that’s being lost more and more as our industry gets bigger. They think the adult-use cannabis market would be bigger than the medical marijuana market.”
But, as this research suggests, the differences aren’t nearly as sharp and distinct as we might have thought. Medical and adult-use cannabis just might turn out to be precisely the same exact thing.
The post Adult-Use Cannabis Reduces Prescription Drug Demand appeared first on Cannabis Now.
Guests Kris Krane and Heather Sullivan speak with host Ben Larson about the recent court ruling finding that Delta 8 THC is legal, the vetoing of legal cannabis by the governor of Delaware, the embrace of legalization by Rhode Island, and a check-in on post-legalization life in New York . Produced by Shea Gunther.
The top cannabis regulator in New Jersey faced tough questioning on Thursday during a marathon hearing that looked into the oft-delayed rollout of the state’s adult-use weed program.
Jeff Brown, executive director of the New Jersey Cannabis Regulatory Commission, testified before the Senate Judiciary Committee during a hearing that reportedly lasted five hours.
The hearing came less than a month after recreational cannabis sales kicked off in the Garden State, a launch that was typified by one delay after another.
The troubled launch prompted Nicholas Scutari, the president of the New Jersey state Senate, to call for the hearings back in March.
“I’m confident that if we did not start this process, the adult weed market would still not be open in New Jersey,” Scutari, a Democrat who pushed for cannabis legalization for years, said at the hearing on Thursday, as quoted by NJ.com.
The hearing also featured “industry leaders and marijuana advocates [who] discussed the pace of setting up the Garden State’s recreational market, scrutinized pricing issues, and griped over still-unwritten regulations for employers seeking clarity on when they can and can’t discipline employees who use cannabis,” according to the New Jersey Monitor.
NJ.com reported that Wesley McWhite, the state’s Cannabis Regulatory Commission’s director of diversity and inclusion, also testified with Brown.
Legal adult-use cannabis sales began in New Jersey last month, drawing more than 12,000 customers who generated almost $1.9 million in sales on the first day.
But that grand opening came after the state had pushed back the launch.
In February, New Jersey Gov. Phil Murphy said the state was hopefully “within weeks” of its first adult-use sales.
But in March, the Cannabis Regulatory Commission pushed back the scheduled launch of sales after opting against awarding licenses to several would-be dispensaries.
“We may not be 100% there today, but I assure you we will get there,” Brown said following that delay. “We have a few things to address and when we address them I’m happy to return to this body with a further update.”
That was the last straw for Scutari, who said at the time that he planned to hold special legislative hearings to look into the delays.
“These delays are totally unacceptable,” Scutari said in a statement at the time. “We need to get the legal marijuana market up and running in New Jersey. This has become a failure to follow through on the public mandate and to meet the expectations for new businesses and consumers.”
In calling for the hearings, Scutari said he wanted “explanations on the repeated hold-ups in expanding medical dispensaries to sell recreational marijuana and in the opening of retail facilities for adult-use cannabis,” and to learn “what can be done to meet the demands and reduce the costs of medical marijuana.”
On Thursday, Brown, according to NJ.com, “said the CRC delayed issuing licenses in March over fears there would not be enough supply of marijuana for both the medical and recreational markets.”
The New Jersey Monitor reported that the “lack of edibles in the Garden State was also a topic Thursday,” noting that “people can find flower, oils that can be vaped or ingested, and limited gummies” in dispensaries.
According to the publication, “edibles like cookies and brownies aren’t allowed under the current law, Brown noted, and any change to that would need to be approved by the Legislature.”
“There are ingestible avenues to purchase and consume, and we hope to expand those in the future. I don’t have a specific timeline,” Brown said, as quoted by the Monitor.
Per the Monitor, Scutari replied: “I’ll call you on that.”
The post New Jersey Regulator Grilled at Hearing Over Sluggish Adult-Use Weed Launch appeared first on High Times.
Host Lewis Goldberg and producer Shea Gunther carve out an hour to talk about their origins in the industry, their thoughts on the development of legal psychedelics, and what it means to be happy with your work. Produced by Shea Gunther.
Betty Aldworth and Jeremy Berke join host Heather Sullivan to talk about the state of unionization within the legal cannabis industry as well as the intersection of medical marijuana and cancer treatments. Produced by Shea Gunther.
First-time-guests Sysamone Phaphon, John Farrell, and Nik Kouparanis talk with host Ben Larson about what the world of legal cannabis looks like in the rest of the world. Produced by Shea Gunther.
Andrea Brooks and Sirita Wright joins host Ben Larson to talk about the rise and impacts of hemp-derived psychoactives, the growth and unique challenges of infused beverages, and the current tax landscape for legal marijuana. Produced by Shea Gunther.
Taylor West and Heather Sullivan joins first-time host Jeremy Berke to talk about the MORE Act, which just passed out of the House, as well as the merits and downsides of industry consolidation. Produced by Shea Gunther.